• Tue news: Merck's Keytruda stages comeback in head and neck cancer. GSK, Pfizer RSV vaccine sales fall. Astellas gene therapy bet. Extreme weather —>drug shortages. J&J discontinues bladder cancer drug. See more on our front page

Will the DOW break 13 this month?





Technical analysis says that it is hitting resistance. However, people have learned not to fight the fed. The only prevailing factor propping up the stock market has been the federal reserve. Make no mistake, QE3 is happening.
 




Technical analysis says that it is hitting resistance. However, people have learned not to fight the fed. The only prevailing factor propping up the stock market has been the federal reserve. Make no mistake, QE3 is happening.

Thanks for the reminder - the only thing I'm currently in (for the portfolio that I manage vs my one that LPL manages) is BAC @ $5.67. I think I'm good on that one but will slide a new stop in at $7.67. :cool: